Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analysts maintain a “Hold” consensus on Personalis, with two sell, four hold and four buy ratings. The average 12-month price target is $14.54, below the stock’s cited price of $17.06.
• Personalis reported a quarterly loss of $0.30 per share, missing estimates by $0.04, though revenue of $22.36 million exceeded expectations of $16.69 million. Analysts expect a full-year loss of approximately $1.07 per share.
• Insiders sold 296,233 shares worth about $4.05 million over the past 90 days, including substantial sales by the CEO and CFO; institutional investors and hedge funds own 61.91% of the company.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been assigned an average rating of "Hold" from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.5357.

A number of analysts recently weighed in on PSNL shares. TD Cowen reiterated a "buy" rating on shares of Personalis in a research note on Wednesday, July 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a research note on Friday, July 17th. Craig Hallum cut shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 target price for the company. in a report on Monday, August 24th. Needham & Company LLC downgraded shares of Personalis from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Finally, Zacks Research lowered Personalis from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 21st.

Personalis Stock Up 1.7%

NASDAQ:PSNL opened at $17.06 on Wednesday. The company has a market capitalization of $1.79 billion, a PE ratio of -15.65 and a beta of 2.27. Personalis has a 52-week low of $4.67 and a 52-week high of $18.89. The stock's 50 day moving average price is $14.27 and its 200 day moving average price is $10.11.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analysts' expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. As a group, sell-side analysts anticipate that Personalis will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Aaron Tachibana sold 4,982 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the sale, the chief financial officer owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 296,233 shares of company stock valued at $4,048,636 over the last ninety days. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Personalis

Several institutional investors have recently bought and sold shares of PSNL. Caitong International Asset Management Co. Ltd lifted its stake in shares of Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock worth $27,000 after acquiring an additional 1,479 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Personalis in the fourth quarter valued at about $31,000. Legal & General Group Plc acquired a new position in shares of Personalis during the second quarter worth about $30,000. Quantbot Technologies LP acquired a new position in shares of Personalis during the second quarter worth about $69,000. Finally, BNP Paribas Financial Markets raised its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source